Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
about
Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
P2860
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Clinical Management of Potenti ...... derations and Recommendations.
@en
Clinical Management of Potenti ...... derations and Recommendations.
@nl
type
label
Clinical Management of Potenti ...... derations and Recommendations.
@en
Clinical Management of Potenti ...... derations and Recommendations.
@nl
prefLabel
Clinical Management of Potenti ...... derations and Recommendations.
@en
Clinical Management of Potenti ...... derations and Recommendations.
@nl
P2093
P2860
P921
P1433
P1476
Clinical Management of Potenti ...... derations and Recommendations.
@en
P2093
Aditya Bardia
Beverly Moy
Laura M Spring
Mark L Zangardi
P2860
P304
P356
10.1634/THEONCOLOGIST.2017-0142
P577
2017-07-13T00:00:00Z
2017-09-01T00:00:00Z